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Available online 4 February 2016Background: Patients suffering from Parkinson's disease (PD) display cognitive and neuropsychiatric dysfunc-
tions, especially with disease progression. Although these impairments have been reported to impact more
heavily upon a patient's quality of life than anymotor dysfunctions, there are currently no interventions capable
of adequately targeting these non-motor deﬁcits.
Objectives: Utilizing a rodent model of PD, we investigated whether cell replacement therapy, using intrastriatal
transplants of human-derived ventral mesencephalic (hVM) grafts, could alleviate cognitive and neuropsychiat-
ric, as well as motor, dysfunctions.
Methods: Rats with unilateral 6-hydroxydopamine lesions to the medial forebrain bundle were tested on a
complex operant task that dissociates motivational, visuospatial and motor impairments sensitive to the loss
of dopamine. A subset of lesioned rats received intrastriatal hVM grafts of ~9 weeks gestation. Post-graft, rats
underwent repeated drug-induced rotation tests and were tested on two versions of the complex operant task,
before post-mortem analysis of the hVM tissue grafts.
Results: Post-graft behavioural testing revealed that hVM grafts improved non-motor aspects of task perfor-
mance, speciﬁcally visuospatial function and motivational processing, as well as alleviating motor dysfunctions.
Conclusions:Wereport the ﬁrst evidence of humanVM cell grafts alleviating both non-motor andmotor dysfunc-
tions in an animalmodel of PD. This intervention, therefore, is the ﬁrst to improve cognitive and neuropsychiatric
symptoms long-term in a model of PD.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Dopamine1. Introduction
In Parkinson's disease (PD), a common neurodegenerative disorder
characterized neuropathologically by Lewy body formation and deteri-
oration of the nigrostriatal pathway, patients present with motor, cog-
nitive and neuropsychiatric symptoms. The non-motor dysfunctions
are frequently reported as reducing quality of life and impacting on
the well-being and health status of people with PD to a greater degree
than any motor complications (Duncan et al., 2014; Hinnell et al.,
2012). Non-motor symptoms are increasingly recognized as core dys-
functions of the disease, and indeed are typically observed prior to the
onset of overt motor impairments (Hawkes, 2008; Meissner, 2012).
Multiple aspects of function can become compromised, including im-
paired executive function, increased apathy, depression, impaired
visuo–spatial abilities, and reduced motivation.iff University, Museum Avenue,
ardiff Metropolitan University,
ical Neurosciences, School of
Wales CF24 4HQ, UK.
. This is an open access article underThe effective alleviation of non-motor dysfunction is a critical ele-
ment of any effective therapy, but there are currently no interventions
that are capable of adequately targeting both motor and non-motor
impairments.While pharmacological therapies, such as L-dopa, alleviate
somemotor dysfunctions in themajority of patients, they often have no
impact upon, or can even impair, cognitive performance (Hernández
et al., 2014; Obeso et al., 2011; Schneider et al., 2013; Zibetti et al.,
2013). Systemic administration of dopamine-enhancingdrugs is unlike-
ly to improve cognitive dysfunctions effectively, given that both too lit-
tle and toomuch dopamine are known to impair neural processing, and
that optimal levels differ across different sub-regions of the brain (Cools
and D'Esposito, 2011).
Cell replacement therapies hold considerable promise as a thera-
peutic intervention. In open-label clinical studies, intrastriatal grafts of
foetal ventral mesencephalon (hVM; the region of the human foetal
brain in which the nigrostriatal dopamine cells develop) produced
long-term improvements in motor function, removing the need for
pharmacological interventions in some patients (Freed et al., 1992;
Kefalopoulou et al., 2014; López-Lozano et al., 1997; Wenning et al.,
1997; Lindvall, 1997). Transplants of hVM have provided proof-of-
principle that implantation of dopamine neurons can produce function-
al beneﬁt and are pivotal in paving the way for transplantation of stemthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ability of hVM grafts to alleviate any non-motor dysfunctions observed
in PD patients. Cognitive disability has not been comprehensively
assessed in many clinical trials of transplantation in PD, making it difﬁ-
cult to determine the impact of cell therapies on this functional output
(Ostrosky-Solís et al., 1988; Sass K et al., 1995).
Results obtained from rodent PD models, utilizing rat-derived
VM, have revealed some improvements in visuo–spatial performance
(Dowd and Dunnett, 2004; Heuer et al., 2013).While these studies pro-
vide encouraging data regarding the ability of cell therapies to target
one aspect of non-motor impairment, it has yet to be revealed whether
hVM can endow such effects (Lelos et al., 2012) and whether multiple
domains of non-motor dysfunctions can be improved. Although several
studies report long-term survival of hVM tissue in the rodent brain
(Brundin et al., 1986; Strömberg et al., 1989, 2001, 2010), few studies
investigated the functional efﬁcacy of these grafts. For example, it has
been reported that hVM grafts of 6–9 weeks gestation can reduce
drug-induced rotational bias (Brundin et al., 1986, 1988; Clarke et al.,
1999; Grealish et al., 2010; Strömberg et al., 1995, 1986). What has
not been demonstrated is the capacity of these cells to impact upon
the more debilitating non-motor dysfunctions that manifest in PD.
Thus, the aim of this study was to investigate the functional impact of
hVM grafts on non-motor and motor impairments.
2. Methods
To test our hypothesis, rats were pre-trained on a complex operant
choice reaction time task in a 9-hole box apparatus, whichmeasures vi-
suospatial function and incentive motivation. Rats received lesions of
the nigrostriatal pathway, by infusion of the selective neurotoxin 6-
hydroxydopamine. After the grafting of hVM ectopically into the dorsal
striatum, ratswere tested for drug-induced rotation, followed by testing
on two versions of the choice-reaction time task.
2.1. Subjects
Twenty-six female Lister-hooded rats (Charles River, UK) were
maintained on a 14:10-h light/dark cycle. All rats were food restricted
oneweekbefore commencing operant training/testing and for thedura-
tion of any operant experimental work, in order to motivate learning in
the operant task. During food restriction, rats weremaintained at 90% of
their baseline weights. All experiments were conducted in compliance
with the UK Animals (Scientiﬁc Procedures) Act 1986 under Home
Ofﬁce Licence No. 30⁄2498 and with the approval of the local Cardiff
University Ethics Review Committee.
2.2. Apparatus
2.2.1. Operant chambers
The 9-hole chambers (Paul Fray, U.K.) were constructed of alumini-
um (25 × 25 cm) with a grid ﬂoor, and the backwall housed an array of
nine holes, each of which contained a light-emitting diode to provide a
visual stimulus, and a vertical infrared beam with a photocell detector,
which detected nose poke responses into the hole. A food magazine in
the middle of the opposite wall signalled the delivery of 45-mg sucrose
reward pellets (TestDiet, IN, USA). On-line data collection was con-
trolled by BNC software (Campden Instruments, UK).
2.2.2. Rotometers
A bank of 16 automated rotometer bowls (Rotorat, Med Associates,
VT) (Ungerstedt and Arbuthnott, 1970) recorded the frequency of
amphetamine-induced rotation for 90 min after i.p. injection of
2.5 mg/kg methamphetamine hydrochloride (Sigma-Aldrich, UK).
Apomorphine-induced rotations were recorded for 60 min after
subcutaneous injection of 0.05 mg/kg apomorphine hydrochloridehemihydrate (Sigma-Aldrich, UK). Rotation scores expressed as an
average of ipsilateral minus contralateral rotations.
2.3. Experimental design
Rats (n = 26) were pre-trained for 7 weeks in the 9-hole operant
chambers on the Bilateral choice reaction time task. A cohort of rats
(n=18) received infusion of 6-OHDA into theMFB. Eight rats remained
as unoperated controls. At 2 weeks post-lesion, all rats underwent
amphetamine-induced rotations and were tested in the operant box
apparatus for 5 days to measure lesion-induced deﬁcits. Rats were sep-
arated into equal groups (lesion only versus grafted) based on rotation
and operant performance. One cohort of lesion rats (n = 10) then re-
ceived intrastriatal transplantations of hVM tissue. All rats were immu-
nosuppressed daily with intraperitoneal injections of 10 mg/kg
cyclosporine (Sandoz Pharmaceutical, U.K.). Amphetamine-induced ro-
tations were tested at 3 week intervals. At 14 weeks post-graft, rats
were re-tested in the operant boxes, using two distinct versions of the
task. At 20 weeks, rats underwent an apomorphine-induced rotational
challenge and were then perfused and brains tissue taken for histologi-
cal analysis.
2.4. Behavioural testing
Pre-training was conducted as previously described (Lindgren et al.,
2014) (Fig. 1). Brieﬂy, the central location in the array and a lateral
“response” location one space away on the left and right of the central
hole were utilized. Rats were trained to hold their noses in the central
location for a variable delay to initiate brief presentation (200 ms) of a
lateralised light. A correct response into the lateralised hole triggered
delivery of a sucrose pellet into the magazine (45 mg, TestDiet, IN,
USA). Errors were recorded and resulted in a 2 s time out. Failure to
maintain hold in the central location for the variable delay duration re-
sulted in a time out and an unusable trial. The session duration was
30 min.
The behavioural outputswere calculated as follows. Trials usable: tri-
als in which the rat responded to the illuminated centre hole for the re-
quired delay, initiating the presentation of the stimulus light. Accuracy:
percentage of correct responses, divided by the total number of re-
sponses made into the two available locations. Reaction time: mean la-
tency to initiate a response by withdrawal of the nose from the centre
hole location after the onset of the lateral stimulus light (on correct re-
sponses only).Movement time: mean latency to execute the lateralised
nose poke response after removal of the nose from the centre hole (on
correct responses only).
Post-graft, rats were tested in alternating one week blocks on the
version of task described above (‘Bilateral’) and on an alternative ver-
sion of the task (‘Unilateral’). The Unilateral version of the task, in
which both response locations are located on one side only, was used
to probe response choice within contralateral space (Heuer et al.,
2013; Ungerstedt and Arbuthnott, 1970). This more challenging version
probes visuo–spatial performance by revealing more precisely the abil-
ity of the rat to generate and execute responses on the side of the body
contralateral to the dopamine-depleting lesion. The same response
location on the left was utilized (now referred to as ‘Near’) and the
space immediately to the left of it was exposed (‘Far’).
2.5. Surgical procedures
2.5.1. Lesions
Rats were anaesthetised with isoﬂourane (2–4% with carrier gases
oxygen and nitrous oxide) in a stereotaxic frame. TheMFBwas targeted
with an injection of 12 μg (freebase) of 6-OHDA (Sigma; 3 μl of 4 μg/μl
solution at 1 μl/min with 2 min diffusion) in 0.01% ascorbate saline at
stereotaxic coordinates AP−4.4 and ML ±1.0 (from bregma) and DV
−7.8 below dura.
Fig. 1. Schematic representation of the two versions of the operant choice reaction time task. TheBilateral version (left) required the rat to hold its nose in the centrehole of the array until a
stimulus light ﬂashed brieﬂy on the ipsilateral or contralateral side. The Unilateral version (right) was similar, except that the stimuli were both situated on the side of the body
contralateral to the lesion, with one hole in the same location as the Bilateral version (Near), and the other one hole further away (Far).
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Human foetal tissue was collected from medical terminations of
pregnancywith full donor consent, through the SWIFT human foetal tis-
sue bank (http://www.biobankswales.org.uk/swift-research-tissue-
bank), under UK Human Tissue Authority research licence (no. 12457)
held by Cardiff University, and with ethical approval of the project
from the Bro Taf local research ethics committee. Gestational age was
estimated through ultrasound scan prior to the procedure in combina-
tion with measurement of foetal regions (Evtouchenko, 1996).
The hVM tissuewas harvested from four foetuses of ~9weeks gesta-
tion, with a mean (and standard deviation) crown-rump length of
26.4 mm (±1.96). Tissue was used as individual suspensions and not
pooled. Tissue was incubated at 37 °C for 20 min in TryplE Express
(Life Technologies Inc) containing 20 U/ml Dornase alfa (Pulmozyme,
Roche). Tissue was dissociated by trituration in 200 μl of DMEM/D to
obtain a quasi-single cell suspension. The viability for each sample
was estimated as N95%. Each rat received 2 × 2 μl suspension containing
approximately 500,000 cells in total. Cells were implanted at a rate of
0.5 μl/min and distributed over two stereotaxic sites (AP: +0.5, ML:
−3.0 mm and AP: +1.2, ML: −2.6 mm) at depths of −4.5 and
−3.7 mm.
2.6. Perfusion
Rats were terminally anaesthetized with sodium pentobarbital
(Euthatal, Merial, UK) and sacriﬁced by transcardial perfusion with
0.01 M phosphate buffer followed by 1.5% paraformaldehyde (pH 7.4;
Sigma-Aldrich). Brains were post-ﬁxed for 24 h in 1.5% PFA before
being transferred to 25% sucrose solution. Tissue was sectioned on a
freezing sledge microtome at 40 μm thickness in a 1:12 series.
2.7. Bright-ﬁeld and ﬂuorescent immunohistochemistry
Free-ﬂoating sections were blocked in 3% normal serum, then incu-
bated in primary antibody with 1% serum overnight at RT. Tissue was
incubated in secondary antibody (1:200) with 1% serum for 3 h, then
immersed in an avidin-biotinylated enzyme complex (Vector Labo-
ratories) for 2 h, then either stained with DAB or Vector SG (Vector
Laboratories).The primary antibodies used in either bright-ﬁeld or ﬂuorescent im-
munohistochemistry were tyrosine hydroxylase (TH, 1:1000, Millipore,
AB1542); Girk2 (1:500, Alomone, APC-006); Calbindin (1:1000, Sigma,
C9848), and HuNu (1:1000, Millipore, MaB 1281).
2.8. Statistics
Statistical analyses were conducted using SPSS (v20, IBM) or, to ad-
just for missing values, GenStat (v16, VSN International). Newman
Keuls method was used for post-hoc analyses. One grafted rat was re-
moved from the behavioural data due to not responding in the operant
box during the post-graft testing period.
3. Results
3.1. Histological analyses
At 20 weeks post-graft, surviving dopamine-rich grafts were
revealed by staining for tyrosine hydroxylase (TH; see Fig. 2). On aver-
age, there were over 2000 TH positive cells in each graft, with over
50% of these labelling as Girk2 positive (a marker for A9 nigral subtype
of dopamine neurons) and ~40%were Calbindin+ve (amarker for A10
ventral tegmental subtype of dopamine neurons). The variability in the
number of cells surviving is likely related to variability between donors.
TH +ve ﬁbres were observed innervating the host tissue, with a pro-
nounced bias towards projecting to the medial region of the striatum.
Some innervation of TH positive ﬁbres into the ventral striatum was
also evident.
3.2. Drug-induced rotational bias
In the amphetamine-induced rotation task (Fig. 3A), Lesion rats
maintained a consistent rotational bias across the test sessions. How-
ever, hVM grafted rats demonstrated a progressive reduction in rota-
tion, until performance was identical to Control rats [Group ∗Week:
F12,138 = 4.71, p b 0.001; effect of Week for hVM rats, p b 0.001]. In
the apomorphine rotation test (Fig. 3B), hVM grafted rats rotated signif-
icantly less than Lesion rats, and instead performed comparably to Con-
trol rats [Group: F2,23= 33.36, p b 0.001; Lesion vs Control and hVM: all
p b 0.001; Control vs hVM, n.s.].
Fig. 2. Immunohistological analysis of hVM tissue at 20weeks post-graft. Immunohistochemistry of TH+ve neurons (brown) and HuNu (blue) in the hVM graft (top panel). From left to
right, images depict representative tissue from a Control rat (A), Lesion rat (B) and a large hVMgraft (C). The central panel depicts A9 TH+veneurons (green) co-labelledwith Girk2 (red,
D); A10 TH+ve neurons (green) co-labelled with Calbindin (red, E); ×10magniﬁcation of hVM cells with TH+ve neurons stained in brown and HuNu+ve cells in blue (F). The bottom
panel depicts the number of TH+ve cells per individual graft (G) and as a groupmean (H), as well as the proportion of girk2+ve (I) and calbindin+ve (J) cells out of the total number of
TH + ve neurons. Scale bar = 1000 μm. Error bars = ± standard error of mean.
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Data from the last week of the Bilateral version of the task, 18weeks
post-graft, are presented in Fig. 4. The results reveal improved execution
of usable trials and improved accuracy in rats grafted with hVM tissue,
relative to lesion rats.
3.3.1. Usable trials
Rats grafted with hVM tissue made signiﬁcantly more usable trials
than the Lesion cohort, and a greater percentage of their total trials
were usable, revealing the ability of hVM tissue to improve the rats'mo-
tivation to initiate trials [Fig. 4A; Group: F2,22 = 40.0 and 46.82, respec-
tively, ps b 0.001; hVM vs Lesion, ps b 0.05].
3.3.2. Accuracy
On the contralateral side, hVM grafts signiﬁcantly improved ac-
curacy relative to the Lesion rats, making the performancecomparable to Control rats [Fig. 4B; Group ∗ Side: F2,16 = 9.38,
p b 0.005; on contra side, Lesion vs Control and hVM, ps b 0.05;
hVM vs Control, p b 0.05].
3.3.3. Reaction time
On the contralateral side, the reaction time was signiﬁcantly
slower for both Lesion and hVM rats, compared to control [Fig. 4C;
Group ∗ Side: F2,16 = 8.29, p b 0.001].
3.3.4. Movement time
The latency to move to the response location was longer on the con-
tralateral side for Lesion and hVM grafted rats, compared to control
[Fig. 4D; Group ∗ Side: F2,16 = 9.51, p b 0.005].
3.4. Unilateral choice reaction time task
Data from the last week of the Unilateral version of the task,
19weeks post-graft, are presented in Fig. 4. The results reveal improved
Fig. 3.hVMgrafts reducedrug-induced rotational bias.Meannet rotations perminute for rats injected i.p.with2.5mg/kgmethamphetamine (A). Rotational biaswasmeasuredpost-lesion, then
at 3weekly intervals, between 4 and 19weeks post-graft. Apomorphinewas injected subcutaneously at 0.05mg/kg in a single rotational test, whichwas conducted at 20 weeks post-graft (B).
Signiﬁcant effect of Group: ***p b 0.001. Signiﬁcant difference between hVM grafted rats and Lesion rats: ###p b 0.001. Error bars =±standard error of mean.
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in rats grafted with hVM tissue, relative to lesion rats.
3.4.1. Usable trials
hVM rats successfully completed signiﬁcantly more usable trials
than the Lesion cohort and a greater percentage of total trials were
usable [Fig. 4E; Group: F2,22 = 84.01, p b 0.001, hVM vs Lesion ps b 0.01].
3.4.2. Accuracy
Rats grafted with hVM tissue demonstrated signiﬁcantly greater
response accuracy than Lesion rats [Fig. 4F; Group ∗ Side: F2,16 =
28.08, p b 0.001, hVM vs Lesion hVM, p b 0.01].
3.4.3. Reaction time
The latency to react was shorter for Control rats than Lesion or hVM
rats [Fig. 4G; Group: F2,22=12.72, p b 0.001]. No effect of hVMgraft was
evident on the reaction time.
3.4.4. Movement time
On the far hole, hVM graft rats were signiﬁcantly faster to respond
than Lesion rats [Fig. 4H; Group ∗ Side: F2,16 = 18.92, p b 0.001, Lesion
vs hVM, p b 0.01].
4. Discussion
In this study, we tested the hypothesis that human-derived cell
replacement therapies can alleviate non-motor cognitive and neuro-
psychiatric deﬁcits that manifest in neurodegenerative disease states.
We believe this to be the ﬁrst clear evidence that hVM transplants
have the capacity to improve performance on non-motor aspects of
impairment associated with the loss of dopamine innervation, in a rat
model of PD.
The histological ﬁndings, including number of surviving human-
derived TH +ve neurons, the proportion of A9/A10 subtypes, and the
degree of histological variability, was in line with previous observations
(Grealish et al., 2010). Signiﬁcant innervation of the dopaminergic pro-
jections into the host tissue was observed, with a bias towards innerva-
tion of the more medial neostriatum and ventral striatum. Two distinct
tests of drug-induced rotation revealed signiﬁcant alleviation of rota-
tional bias in rats grafted with hVM tissue, indicating that hVM grafts
survived, integrated into tissue and released sufﬁcient dopamine to
improve the severe turning bias induced by unilateral MFB loss. How-
ever, because these tests bear little relevance to the clinical situation,
it remained important to evaluate the functional efﬁcacy of the hVMtissue on tasks which necessitated skilled motor function and which
comprised elements of non-motor function.
The choice reaction time task (Dowd and Dunnett, 2004; Heuer
et al., 2013) isolates the involvement and processing capacity of a single
hemisphere during a trial. This way, we can observe a within-subject
deﬁcit unilaterally in the rat and performance on motor and non-
motor elements of the task can clearly be dissociated. Although the
Bilateral version of the task reveals impairment in responding to the
contralateral side induced by loss of dopamine, the Unilateral version
of the task demonstrates that, under alternative conditions, lesion rats
are capable of generating motor responses in contralateral space.
The latency to move to, and respond in (movement time), the far
hole was shorter in hVM grafted rats than in lesioned animals in the
Unilateral version of the task. A trend towards reduced movement
time can be observed numerically in the Bilateral version, although
this effect did not reach signiﬁcance. Taken together with the results
of the drug-induced rotational tests, this suggests that overt motor dys-
functions were broadly improved by the presence of the hVM graft. The
latency to react (reaction time)wasnot alleviated by the presence of the
hVM grafts, which is in accordance with previous studies that utilized
rat-derived VM grafts (Dowd and Dunnett, 2004; Heuer et al., 2013).
This suggests that attentional deﬁcits have not been improved by the
hVM transplantation.
More interestingly, we observed an improvement in several of the
non-motor aspects of function in the hVM grafted rats. It has been dem-
onstrated that initiation and completion of usable trials is dependent
upon the propensity to initiate goal-directed behaviours and on themo-
tivational status of the rat (Lelos et al., 2012). Thus, reducing incentive
motivation by speciﬁc-satiety of the sucrose reward has been shown
to reduce the production of goal-directed behaviour and, consequently,
signiﬁcantly decrease the number of trials executed (Lelos et al., 2012).
Loss of nigrostriatal dopamine does not disrupt reward or hedonistic
processing per se, but rather it decreases the motivation to work for a
reward (Drui et al., 2014; Favier et al., 2014; Schmidt et al., 2008;
Shiner et al., 2012). In accordance with this, PD patients present with
deﬁcits in mood, decreased motivation and apathetic behaviour
(Aarsland et al., 2005). The data presented here demonstrates that rein-
nervation of dopaminergic projections into the striatum from hVM
grafts resulted in increased numbers of trials being initiated and com-
pleted, which reveals enhanced motivational status and improved
goal-directed performance.
The hVM grafted rats also demonstrated improved accuracy of
performance relative to Lesion rats. It has been suggested that loss of
dopamine impairs the ability to direct responses in contralateral
space, potentially as a result of processing a distorted representation
Fig. 4. hVM grafts improve non-motor andmotor performance on an operant task. Performance during the ﬁnal week (18weeks post-graft) on the Bilateral version (left column) and the
Unilateral version (right column) of the choice reaction time task. Data portray the total number of usable trials and the percentage of total trials thatwere usable, accuracy, latency to react
and latency to respond. Signiﬁcant difference from Control rats: **p b 0.01, *p b 0.05, (*)p b 0.1 (n.s.). Signiﬁcant difference from Lesion rats: ††p b 0.01, †p b 0.05. Error bars=±standard
error of mean.
59M.J. Lelos et al. / Experimental Neurology 278 (2016) 54–61of response space (Brown and Robbins, 1989, 1991). Our data demon-
strate that while contralateral responses are impaired in Lesion rats in
the Bilateral task, they are able to respond with high accuracy in thesame response hole (previously impaired location; near hole) when a
second, more distal, response location is exposed (Unilateral version).
Thus, responding into the near hole is not disrupted per se, but instead
60 M.J. Lelos et al. / Experimental Neurology 278 (2016) 54–61the ability to direct actions in space is impaired. It is possible to con-
clude, therefore, that the deﬁcit in responding to the far, but not the
near, hole is a result of an inability to code movements appropriately
in space, while the ability to generate movement remains intact
(Brown and Robbins, 1989, 1991).
The hVM grafts alleviated both the motor and non-motor deﬁcits.
Although similar ﬁndings have been observed after transplantation
of rat-derived VM, this is the ﬁrst evidence of hVM grafts alleviating
these deﬁcits. Indeed, while rat VM improved non-motor impairments
at 12 weeks post-graft (Dowd and Dunnett, 2004; Heuer et al., 2013),
we now ﬁnd that hVM requires a longer (18–20 weeks) maturation pe-
riod before functional recovery is observed in these tasks of non-motor
function.
The recovery of these behaviours may be explained by the speciﬁc
pattern of innervation and the heterogeneous nature of the striatum.
Medial regions of the striatum support cognitive and goal-directed be-
haviours, as would be expected from the pattern of innervation from
the association cortex areas. Conversely, the lateral striatum is impor-
tant for motor function and receives heavy afferent connections from
motor cortex regions. Additionally, the observed innervation of the ven-
tral striatum may account for the improvement in non-motor dysfunc-
tions. The mesolimbic dopamine pathway, which comprises efferent
dopaminergic VTA projections to the ventral striatum (nucleus accum-
bens), is a critical system involved in motivation and incentive salience
(Haber, 2014). Indeed, to further support this, Piccini and colleagues
found that PDpatients that showed the least clinical improvement dem-
onstrated early or continued loss of ventral striatal dopamine, relative to
patients that beneﬁtedmostwhohadmore intactmesolimbic pathways
(Piccini et al., 2005). Histological observation of the tissue grafts re-
vealed greater propensity for the dopaminergic projections to innervate
the medial and ventral striatum. While the reason for this innervation
pattern remains unknown, we can nevertheless deduce that the im-
provements in non-motor function may be driven by this pattern of
subregional recovery.
The operant task probes non-motor functions that have been shown
to be disrupted in PD patients, where changes in mood, decreased mo-
tivation and apathy are commonly seen with disease progression
(Aarsland et al., 2005). It has been suggested that the loss ofmotivation-
al processing that underlies decreased goal-directed behaviour in ro-
dents is akin to apathetic behaviour in patients (Levy and Dubois,
2006). Apathy is known to impact severely on an individual's ability to
function normally, and thus improvement in this neuropsychiatric
symptom is critical for patients with PD. Here we have shown for the
ﬁrst time that alleviation of apathetic-like behaviour, and the con-
sequent reinstatement of voluntary goal-directed behaviours, can be
observed after implantation of hVM grafts.
Visuospatial function is disrupted in PD, insofar as the ability to ap-
propriately direct responses in space is reduced. Patients demonstrate
visuospatial deﬁcits shown to be related to higher-order perceptual
motor dysfunction, rather than disruption of ﬁne motor control
(Richards et al., 1993). As a result, it has been suggested that pa-
tients inappropriately utilize sensory information accurately to
plan and execute complex movements (Richards et al., 1993). Criti-
cally, we have demonstrated the functional efﬁcacy of hVM grafts by
revealing an improvement in visuospatial processing capabilities in
rats that received the cell therapy.
It is increasingly recognized that patients with PD not only suffer
from a range of non-motor dysfunctions, but also that these often man-
ifest before the onset of motor symptoms and can be some of the most
debilitating aspects of the disease (Hawkes, 2008; Meissner, 2012).
Pharmacological interventions are typically not capable of alleviating
these non-motor dysfunctions. Dopaminergic drugs improve motor
dysfunctions when ﬁrst administered to patients, but the effect on
neuropsychological function is less clear. Improvements in a set-
switching task have been reported after administration of levodopa
(Cools et al., 2001; 2003), but also signiﬁcantly impaired probabilisticreversal learning (Cools et al., 2001) and impaired decision making
due to increased impulsivity (Cools et al., 2003). On two reaction time
tasks, apomorphine was reported to impair reaction time performance
(Müller et al., 2002; Costa et al., 2003). Given that each brain region
has different basal and optimal levels of dopamine, it is unsurprising
that systemic administration would cause imbalance in other regions,
resulting in diverse changes inneuropsychiatric and executive functions
(Cools and D'Esposito, 2011).
After chronic ingestion of these drugs, initial improvements were
reported on several tasks, which ultimately worsened over time
(Kulisevsky et al., 2000). Other studies report no improvement in
cognitive function after long-term levodopa, or levodopa plus dopamine
agonist, therapy (Rektorová et al., 2005; Relja and Klepac, 2006). Interest-
ingly, however, it has recently been shown that intrajejunal infusion of
levodopa over 6 months may improve some non-motor symptoms, in-
cluding sleep, attention/memory and gastrointestinal issues (Honig
et al., 2009). Although improvements in perception, mood and cognition
did not meet conventional levels of signiﬁcance in this study, a trendwas
observed (Honig et al., 2009). Thus, there is little evidence to suggest that
oral administration of dopaminergic drugs, as acute or chronic treat-
ments, may be a suitable therapy for alleviating the non-motor dysfunc-
tions that manifest in PD.
Cell replacement therapies have an advantage insofar as replace-
ment of lost neurons can be targeted to each patient according to specif-
ic patterns of denervation, thereby allowingmore precise reinnervation
of the neurotransmitter. Using this method, we have demonstrated the
ability of hVM grafts to alleviate cognitive, neuropsychiatric and motor
impairments. This opens up the real possibility of utilizing human-
derived cell therapies to target the non-motor impairments that manifest
in PD. Thus, by improving non-motor deﬁcits, it may be possible to im-
prove the quality of life for people with PD.
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